Biotech Values

[jq1234]

Royalty from THRX/GSK respiratory programs definitely COULD generate $5.5B royalty to THRX. The problem with ELN deal is it only includes FF/VI, UMEC/VI, MABA 081 monotherapy, VI monotherapy, not any combination of MABA 081, nor UMEC/VI/FF combination:

The transaction does not include any royalty participation interest associated with UMEC/VI/FF, an investigational medicine also in development under the LABA collaboration with GSK.

......

The transaction does not include any royalty participation interest associated with MABA ‘081 in combination with any other therapeutically active component, including an inhaled corticosteroid, or any other MABA compound as monotherapy or in combination.